Gates urges collective effort to speed up research on microbicides

Bill and Melinda Gates have called for greater efforts to speed up research on what they claim will be the next big breakthrough in the fight against AIDS - the discovery of a microbicide - an oral prevention drug - that can block the transmission of HIV. The power of HIV prevention should be in the hands of women, they said.

Speaking at the opening plenary of the 16th international conference on HIV/AIDs on 13 August, Mr Gates said that the world was doing more than ever before to tackle the disease which infects 90 million people in Africa alone. He cited the work of the Global Fund, which he commended for scaling up access to treatment and preventive tools, but stressed that more funding must be found, particularly for preventative medicine.

"We have to understand that the goal of universal treatment - or even the more modest goal of significantly increasing the percentage of people who get treatment - cannot happen unless we dramatically reduce the rate of new infections," said Mr Gates.

One of the most widely practiced approaches to prevention is the ABC programme, "Abstain, Be faithful, use Condoms". But this approach has its limits, said Mr Gates. Abstinence is often not an option for poor women and girls who have no choice but to marry at an early age. Being faithful will not protect a woman whose partner is not faithful. And using condoms is not a decision that a woman can make by herself.

Another approach is male circumcision, and Mr Gates referred to research findings which suggest that it could significantly reduce the spread of HIV. "This is exciting - and if male circumcision truly is effective, we should make it widely available," said Mr Gates. "But, like using condoms, circumcision is a procedure that depends on a man."

Instead, more research on microbicides should be undertaken. Microbicides are formulated as foams, gels, creams, impregnated sponges, suppositories, and films. Designed to be inserted into the vagina prior to sexual intercourse, such products have the potential to be female-controlled, enabling women at risk of HIV to protect themselves without partner consent. And while there is promising research to report, Mr Gates said that the world has not done nearly enough to discover these new tools - "and I include our foundation in that assessment."

"All of us who care about this issue should have focused more attention on these tools, funded more research, and worked harder to overcome the obstacles that make it difficult to run clinical trials. Now we need to make up for lost time," he added.

Also speaking at the open plenary was Melinda Gates. She too highlighted the need to accelerate research in this area. "When it comes to stopping this disease, there is no silver bullet. We need to be much more aggressive about getting all of today's prevention tools to everyone who needs them. And we need a constant stream of new innovations - especially those that put the power to prevent HIV in the hands of women," she said.

Mrs Gates continued by saying that while the Gates Foundation would continue to invest in research on microbicides and other preventive tools, and do what it could to remove the roadblocks that stand in the way of trials, it could not go it alone: "We all have a role to play."

She called on AIDS activists to use their influence to push for more research into prevention and to insist on bringing the tools already available to the people who need them. "Nobody has the power you have to focus attention, apply pressure, and get action," she added.

Governments too should make the search for new prevention tools, such as microbicides, more of a priority for funding. They should also host clinical trials, and use their influence to ensure that the trials run smoothly. The WHO, UNAIDS, and other organisations should also help develop common ethical standards for clinical trials so they can start faster and run without interruption.

Turning to industry, Mrs Gates called upon pharmaceutical companies to invest more in research and development for preventive tools, including microbicides, and to do more to share treatment drugs with researchers who want to test whether they can also be effective for prevention.

"Researchers can help test the drugs more quickly by developing novel trial designs, finding faster ways to analyse data, and coming up with biomarkers that can help test a hypothesis without needing a clinical trial of 10,000 patients. They should also make sure that when clinical trials are run, they benefit those who are in greatest need," she said.

"If all these players do their part, we will move forward, as fast as science can take us, to discoveries that can help block the transmission of HIV. This goal is worth our greatest efforts; it could very well be the turning point that leads to the end of this disease," she concluded.

For more information, please visit:
http://www.aids2006.org

Copyright ©European Communities, 2006
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg – http://cordis.europa.eu.int. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Northern Ireland Completes Nationwide Ro…

Go-lives at Western and Southern health and social care trusts mean every pathology service is using the same laboratory information management system; improving efficiency and quality. An ambitious technology project to...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...

Groundbreaking TACIT Algorithm Offers Ne…

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment...

The Many Ways that AI Enters Rheumatolog…

High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in systemic sclerosis (SSc). But AI-assisted interpretation has the potential...